# Retro Biosciences Longevity startup bankrolled almost single-handedly by [[Sam Altman]] (~$180M), targeting a 10-year extension of healthy human lifespan via cellular reprogramming. Raised at a $1.8B valuation in May 2026; its first clinical trial — an Alzheimer's pill — expects data in late 2026. A keystone of the tech right's longevity portfolio alongside Altos Labs ($3B launch, Bezos-backed) and [[Bryan Johnson]]'s Blueprint, and a live example of frontier-lab wealth converting into post-FDA biomedical ambition. > Status: stub — expand with the cellular-reprogramming science, the Altman conflict-of-interest angle (OpenAI wealth funding private biotech), and the broader longevity movement map. ## See Also - [[Biotech Sector]] - [[Sam Altman]] - [[Transhumanism]]